News

The New York Times Publishes OCRF’s Letter to the Editor 3/30/15

In response to the “Angelina Jolie Pitt: Diary of a Surgery,” Op-Ed, published in The New York Times on March 24, 2015, OCRF co-wrote a Letter to the Editor along with Ovarian Cancer National Alliance, reminding readers that there is still no early detection method for ovarian cancer. We’re... 

Microenvironment Regulates Tumor Suppressor miRNA

Ernst Lengyel, MD, PhD (April 2, 2015) According to a study published in the journal Oncogene, the tumor microenvironment can regulate tumor suppressor miRNA in ovarian cancer cells. The direct interaction of the ovarian cancer cells with mesothelial cells, which cover the surface of the omentum, caused... 

Population Distribution of Lifetime Risk of Ovarian Cancer in the US

(April 1, 2015) A study published in Cancer Epidemiology, Biomarkers and Prevention looks at ovarian cancer risk in the general population.  In U.S. women, lifetime risk of ovarian cancer is 1.37%, but some women are at a substantially lower or higher ovarian cancer risk due to both genetic and lifestyle... 

Intraperitoneal Chemo Associated with Long-Term Survival Advantage

(March 27, 2015) According to research published this week in the Journal of Clinical Oncology, intraperitoneal (IP) chemotherapy is associated with a long-term survival advantage in ovarian cancer.  The advantage of IP over intravenous chemotherapy extends beyond 10 years, and IP therapy enhanced survival... 

Decisions on a Knife-Edge: Risks and Benefits of Fallopian Tube Removal

(March 20, 2015) This excellent, accessible piece in Mosaic Magazine, “Decisions on a Knife-Edge,” explores the difficult choices high-risk women face when considering how to decrease their chances of developing ovarian cancer.  Removing only the fallopian tubes will avoid forcing a woman... 

Tailored Surgical Approach Leads to Better Outcomes in Ovarian Cancer

(March 10, 2015) An algorithm developed at MD Anderson Cancer Center in Houston has dramatically increased complete resection rates in advanced ovarian cancer, giving patients the best possible chance of survival. The work was funded in part by an OCRF research grant to Anil Sood, MD. The results are... 

OCRF Research Finds New Therapeutic Strategy for Ovarian Cancer

Rugang Zhang, PhD (February 17, 2015) OCRF-funded researchers at The Wistar Institute have identified a new therapeutic target in clear cell ovarian cancer, paving the way for what could be the first effective targeted therapy of its kind for the disease. The findings were published online by the journal... 

New Tool Could Speed Development of Ovarian Cancer Drugs

(February 13, 2015) University of Chicago Medicine researchers, including OCRF grantee and Scientific Advisory Committee member Ernst Lengyel, MD, PhD, have built a model system that uses multiple cell types from patients to rapidly test compounds that could block the early steps in ovarian cancer metastasis.... 

Meet OCRF’s 2015 Grantees

(February 11, 2015) Ovarian Cancer Research Fund has announced that $6.1 million has been awarded in scientific research grants for ovarian cancer. This brings OCRF’s total investment in research and related educational and support initiatives to over $65 million. The twenty new OCRF research grants... 

SGI-110 is an Ovarian Cancer Chemosensitizer

Ken Nephew, PhD (February 4, 2014)  In research published last October in Clinical Cancer Research, a team of OCRF-funded investigators showed that a novel therapy can resentisize ovarian cancer to chemotherapy.  The work was led by Dr. Kenneth Nephew, who was funded through an OCRF Program Project...